Login / Signup

Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study.

Eve TessierL Ruffier d'EpenouxMarie-Frédérique LartigueL ChaufourC Plouzeau-JayleR ChenouardFrançois GuérinD TandéC LamoureuxPascale BemerStéphane Corvecnull null
Published in: The Journal of antimicrobial chemotherapy (2024)
We showed low delafloxacin MICs for ofloxacin-susceptible S. epidermidis strains and a double population for ofloxacin-resistant strains. Despite the absence of breakpoints for S. epidermidis, delafloxacin may be an option for the treatment of complex BJI, including strains with MICs of ≤0.094 mg/L, leading to 64% susceptibility. This study underlines the importance for determining specific S. epidermidis delafloxacin breakpoints for the management of BJI on material.
Keyphrases
  • biofilm formation
  • escherichia coli
  • pseudomonas aeruginosa
  • staphylococcus aureus
  • candida albicans
  • clinical trial
  • cross sectional
  • cystic fibrosis
  • clinical evaluation